Fennec Pharmaceuticals (NASDAQ:FENC) is expanding its commercial strategy for PEDMARK, the first and only FDA-approved drug for preventing cisplatin-related hearing loss, as discussed during the H.C. Wainwright 4th Annual BioConnect Investor Conference. The company recorded a quarterly revenue of $15.1 million in Q1 2026, nearly doubling its revenue since CEO Jeff Hackman joined. This revenue corresponds to 300-400 patients annually, including about 100 in the adolescent and young adult (AYA) demographic, which has over 20,000 potential patients in total.
The AYA market represents a significant growth opportunity, ten times larger than the pediatric market. To increase awareness among oncologists, Fennec has expanded its sales force from 10 to 24 territories, targeting more than 5,400 sites across the U.S. Additionally, the company has initiated investigator-sponsored trials to generate real-world evidence that could further support its market position and aims to announce a partnership in Japan soon.
Fennec has also secured market exclusivity through a settlement with Cipla, preventing generics until the end of 2033. The company holds global patents for PEDMARK expiring in 2039, allowing it to explore complementary product offerings aligned with its current customer base.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
